Aernout Luttun1, 10, Marc Tjwa1, 10, Lieve Moons1, Yan Wu4, Anne Angelillo-Scherrer5, Fang Liao4, Janice A. Nagy6, Andrea Hooper4, Josef Priller7, Bert De Klerck2, Veerle Compernolle1, Evis Daci3, Peter Bohlen4, Mieke Dewerchin1, Jean-Marc Herbert8, Roy Fava9, Patrick Matthys2, Geert Carmeliet3, Désiré Collen1, Harold F. Dvorak6, Daniel J. Hicklin4
& Peter Carmeliet11
Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology; University of Leuven, Leuven, Belgium
2
Laboratory of Immunobiology, Rega Institute for Medical Research; University of Leuven, Leuven, Belgium
3
Laboratory of Experimental Medicine and Endocrinology, University of Leuven, Leuven, Belgium
4
ImClone Systems Inc., New York, New York, USA
5
Division of Angiology and Hemostasis, University Medical Center, Geneva, Switzerland
6
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
7
Department of Neurology, Charité, Humboldt-University, Berlin, Germany
8
Cardiovascular/Thrombosis Research Department, Sanofi-Synthélabo, Toulouse Cedex, France
9
Department of Veterans Affairs Medical Center, White River Junction, Vermont and Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA
10
A.L. and M.T. contributed equally to this study.
Correspondence should be addressed to Peter Carmeliet peter.carmeliet@med.kuleuven.ac.be
